ArticleTargeted oncology2026
First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The podcast discusses the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focuses on the efficacy and safety of first-line treatments and sequencing strategies. Patients with ALK-positive NSCLC often need multiple lines of therapy owing to the development of resistance, disease progression, brain metastases, or adverse events. Several options are available for the treatment of ALK-positive NSCLC; therefore, it is important to make an informed decision on which treatment to use in the first line. The podcast also discusses the challenges in treatment sequencing due to high attrition rates from first-line to second-line therapy and the decline in treatment efficacy with each additional line. Real-world data indicate that many patients do not receive second-line therapy after discontinuing first-line treatment. The discussion emphasizes the importance of consideration of drug efficacy, safety outcomes, potential treatment resistance, and development of brain metastases when determining treatment strategies. Ultimately, it is essential to select the best treatment first and proactively manage any potential adverse events to ensure that patients can derive clinical benefit and safely remain on therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.